Hoth Therapeutics Adopts Lantern Pharma's AI Platform for Drug Development

Sep 4, 2025
Hoth Therapeutics is leveraging Lantern Pharma's PredictBBB.ai platform to enhance drug development, as announced in a press release. The AI tool boasts 94% accuracy in predicting blood-brain barrier permeability.

Hoth Therapeutics is leveraging Lantern Pharma's PredictBBB.ai platform to enhance its drug development processes, announced in a press release. The AI tool, part of Lantern's RADR platform, boasts a 94% accuracy rate in predicting blood-brain barrier permeability, a critical factor in drug candidate success.

By adopting this technology, Hoth aims to streamline candidate selection, reduce development risks, and accelerate timelines for therapeutic discovery. The integration of PredictBBB.ai is expected to provide AI-powered insights that increase precision and reduce uncertainty in drug development, potentially leading to faster regulatory pathways and higher value inflection points for Hoth's pipeline.

Lantern Pharma's CEO, Panna Sharma, expressed enthusiasm for the early adoption of their platform by innovators like Hoth Therapeutics, highlighting the potential of PredictBBB.ai to be a game-changer in central nervous system drug development.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.